ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC’s revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma.
ET Wealth Expo: Why market veteran S Naren thinks investors are getting gold, silver and asset allocation all wrong
ICICI Prudential MF’s S Naren warns investors against chasing assets after spectacular rallies, highlighting how silver’s 216% surge drew record ETF inflows before a 27%